Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Slow-releasing composition of estrogen medicine and its preparing process

A technology combining estrogen and sustained-release composition, applied in the directions of drug combination, drug delivery, pharmaceutical formulation, etc., can solve problems such as adverse physiological effects, reduction, etc., to reduce physiological effects, improve stability, prevent and treat male aging Dementia effects

Inactive Publication Date: 2002-11-13
XINJIANG NUZILINE BIO PHARMA CO LTD
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The present invention solves the problem of regular and slow release of conjugated estrogen drugs following oral administration, thereby reducing adverse physiological effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] Below in conjunction with representative example and drug release test, the present invention is further discussed:

[0023] A representative tablet or granule of the estrogen-conjugated sustained-release composition of the present invention contains the following ingredients:

[0024] Ingredients per core: mg

[0025] Lactose 68.8

[0026] Pregelatinized Starch 24

[0027]Conjugated Estrogen API 20

[0028] Magnesium Stearate 1.2

[0029] Povidone (PVP) 6.0

[0030] ER coating composition per drug core: mg

[0031] Eudragit RS 9.7

[0032] Eudragit RL 6.5

[0033] Plasticizer 4.8

[0034] Porogen 6.0

[0035] ER layer, i.e. moisture barrier outside the coating, per drug core: mg

[0036] Vapor barrier material 40

[0037] The preparation method of the conjugated estrogen sustained-release tablet of above-mentioned representative tablet or granule is carried out according to the following steps:

[0038] Step 1: Prepare the drug core (tablet core or granule ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A slowly releasing conjugated oestrogen composition for preventing and treating femal climacteric syndrome, osteoporosis and coronary heart disease and male senile dementia is composed of slow-releasing layer and core containing conjugated oestrogen and progestogen.

Description

technical field [0001] The present invention relates to a pharmaceutical composition containing conjugated estrogen and a preparation method thereof. After oral administration, the sustained release composition of conjugated estrogen drug releases medicine regularly and slowly to treat and prevent menopausal syndrome occurring during female physiological or artificial menopause , prevention and treatment of osteoporosis and coronary heart disease, prevention and treatment of male Alzheimer's disease. Background technique [0002] Since 1930, it was suggested that estrogen be used for the prevention and treatment of menopausal syndrome, thus establishing the basis of estrogen replacement therapy. In the 1950s, the United States first started the commercial production of estrogen replacement therapy products. At present, it is believed that the lack of estrogen after menopause should be adjusted, supplemented and treated like other endocrine g...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/30A61K31/565A61P9/10A61P15/12A61P19/10A61P25/28
Inventor 高晓黎胡海梅
Owner XINJIANG NUZILINE BIO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com